✨ Free AI Report
NeoGenomics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research NeoGenomics, Inc.
Company Research

NeoGenomics, Inc.: Business Overview, Financials & Competitive Analysis

NeoGenomics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Growth-stage cancer diagnostics company expanding test menus and product adoption in large oncology market, offset by current losses and analyst caution. NeoGenomics shows solid revenue growth (10.6% YoY), recent earnings beat expectations, and a strengthening balance sheet, but faces profitability challenges with negative margins and uncertain near-term earnings outlook. Analyst.

What is NeoGenomics, Inc.'s industry? NeoGenomics, Inc. (neogenomics.com) operates in Clinical Laboratory & Cancer Diagnostics. AskCyborg classifies NeoGenomics, Inc. under Clinical Laboratory & Cancer Diagnostics in its company registry.

NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom through two segments: Clinical Services and Advanced Diagnostics. The company specializes in cancer gen...

5/ 10Mixed

Cyborg Score thesis

Growth-stage cancer diagnostics company expanding test menus and product adoption in large oncology market, offset by current...

Read the full analyst-debate transcript →
Industry Clinical Laboratory & Cancer Diagnostics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest NeoGenomics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for NeoGenomics, Inc.

AskCyborg analysts argue the bull and bear cases for NeoGenomics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
NeoGenomics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

NeoGenomics, Inc. Overview

Pro stress-test →

NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom through two segments: Clinical Services and Advanced Diagnostics. The company specializes in cancer genetics testing and information services, serving oncologists, pathologists, hospitals, and pharmaceutical clients with comprehensive oncology diagnostic solutions.

Strategic Profile

Pro stress-test →

The launch of new liquid biopsy products and expanding test offerings position the company to capture market share and benefit from growth in oncology diagnostics demand. 2026 guidance anticipates continued revenue and margin expansion, supported by new product adoption and operational efficiencies, though the company currently operates at a loss as it invests in growth.

Competitive Landscape

Pro stress-test →

Competitors include Quest Diagnostics, PathGroup, and Interpace Biosciences. NeoGenomics differentiates through specialized cancer-focused testing, expanding liquid biopsy capabilities, and strong relationships with oncology providers. The company operates in a consolidating diagnostics market where scale and test menu breadth provide competitive advantages.

Industry Context

NeoGenomics, Inc. operates in Clinical Laboratory & Cancer Diagnostics.

Key facts

Founded: 1998 · Headquarters: Fort Myers, US · Employees: 2,500 · Revenue: $727M · Market cap: $1.28B

What the analysts stress-tested

The top findings that survived the multi-agent debate for NeoGenomics, Inc..

  • Q4 2025 EPS beat estimates ($0.06 vs $0.04) with revenue of $190.17M, representing 10.6% YoY growth
  • Market cap of $1.28B with negative PE ratio (-11.70), reflecting current unprofitability
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Q4 2025 earnings beat with $0.06 EPS and revenue of $190.17M, up 10.6% YoY
  • February 2026Needham raised price target to $15.00 with Buy rating; Piper Sandler raised to $13.00
  • +1 moreTrack every material event for NeoGenomics, Inc. as it happens. Explore monitoring →
Get alerted when NeoGenomics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Diagnostic ServicesLarge diversified clinical laboratory company→Pathology ServicesRegional pathology and laboratory services→Oncology DiagnosticsCancer diagnostic testing company→

Compare NeoGenomics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

NeoGenomics, Inc. operates in Clinical Laboratory & Cancer Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical Laboratory & Cancer Diagnostics research →
NEW · MCP server

Ask your AI assistant about NeoGenomics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare NeoGenomics, Inc. and its top competitor on Cyborg Score”
“What did NeoGenomics, Inc. do this quarter?”
“Is NeoGenomics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does NeoGenomics, Inc. do?+
NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom through two segments: Clinical Services and Advanced Diagnostics. The company specializes in cancer gen...
What is NeoGenomics, Inc.'s Cyborg Score?+
NeoGenomics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are NeoGenomics, Inc.'s main competitors?+
Named competitors include Diagnostic Services, Pathology Services, Oncology Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full NeoGenomics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the NeoGenomics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track NeoGenomics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.